Published in Curr Biol on September 11, 2012
A mitochondrial location for haemoglobins--dynamic distribution in ageing and Parkinson's disease. Mitochondrion (2013) 0.92
An evolutionary roadmap to the microtubule-associated protein MAP Tau. BMC Genomics (2016) 0.77
Chronic oxidative damage together with genome repair deficiency in the neurons is a double whammy for neurodegeneration: Is damage response signaling a potential therapeutic target? Mech Ageing Dev (2016) 0.75
Did α-Synuclein and Glucocerebrosidase Coevolve? Implications for Parkinson's Disease. PLoS One (2015) 0.75
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
A common inversion under selection in Europeans. Nat Genet (2005) 13.66
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol (2004) 9.62
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet (2009) 8.11
Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science (2006) 7.72
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet (2004) 7.69
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A (2000) 5.83
Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability. Nat Genet (2006) 5.59
Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science (2010) 5.42
Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci (2006) 5.32
Alzheimer mechanisms and therapeutic strategies. Cell (2012) 5.24
Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet (2011) 5.01
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med (2010) 4.45
In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A (2011) 4.38
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem (2003) 3.79
The biochemistry of Parkinson's disease. Annu Rev Biochem (2005) 3.79
Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol (2006) 3.72
Evolutionary toggling of the MAPT 17q21.31 inversion region. Nat Genet (2008) 3.42
Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell (2012) 3.39
The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A (2007) 3.39
Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron (1995) 3.37
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci (2009) 3.24
A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet (2011) 3.16
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron (2009) 3.15
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci (2010) 3.14
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science (2003) 2.89
The MAP2/Tau family of microtubule-associated proteins. Genome Biol (2004) 2.80
LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet (2009) 2.55
LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci (2011) 2.52
Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol (2012) 2.48
Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection. Exp Neurol (2005) 2.46
Role of tau protein in both physiological and pathological conditions. Physiol Rev (2004) 2.44
Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol (2011) 2.39
It takes two to tango: regulation of G proteins by dimerization. Nat Rev Mol Cell Biol (2009) 2.34
Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem (1998) 2.32
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol (2012) 2.20
LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res (2008) 2.09
Molecular genetics of Alzheimer's disease. Biol Psychiatry (2000) 1.99
Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci (2009) 1.99
The E46K mutation in alpha-synuclein increases amyloid fibril formation. J Biol Chem (2005) 1.98
Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J Neurosci (2012) 1.95
alpha-Synuclein and neuronal cell death. Mol Neurodegener (2009) 1.85
αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci U S A (2010) 1.83
Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet (2007) 1.72
Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J Neurochem (2007) 1.70
Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet (2007) 1.65
LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci (2012) 1.61
Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett (2004) 1.60
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis (2010) 1.60
Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J Neurosci (2011) 1.56
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet (2011) 1.52
The Roco protein family: a functional perspective. FASEB J (2008) 1.52
Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry (2010) 1.47
Clinical and pathologic features of families with LRRK2-associated Parkinson's disease. J Neural Transm Suppl (2006) 1.46
Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci (2011) 1.42
Evidence suggesting that Homo neanderthalensis contributed the H2 MAPT haplotype to Homo sapiens. Biochem Soc Trans (2005) 1.40
Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm (Vienna) (2011) 1.35
Parkinson's disease and α-synuclein expression. Mov Disord (2011) 1.34
The WD40 domain is required for LRRK2 neurotoxicity. PLoS One (2009) 1.32
Tau isoform regulation is region- and cell-specific in mouse brain. J Comp Neurol (2008) 1.29
A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J Neurosci (2011) 1.25
LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ß. J Neurosci (2010) 1.23
Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One (2012) 1.21
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). Arch Neurol (2008) 1.13
Towards unveiling the genetics of neurodegenerative diseases. Semin Neurol (2012) 1.12
Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience (2012) 1.11
Genetic neuropathology of Parkinson's disease. Int J Clin Exp Pathol (2008) 1.11
LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One (2012) 1.10
Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease. PLoS One (2011) 1.10
Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. Hum Mol Genet (2012) 1.10
LRRK2 Parkinson disease mutations enhance its microtubule association. Hum Mol Genet (2011) 1.08
The genetics of neurodegenerative diseases. J Neurochem (2006) 1.07
Molecular pathogenesis of Parkinson's disease: update. J Neurol Neurosurg Psychiatry (2011) 1.07
Milestones in Parkinson's disease--clinical and pathologic features. Mov Disord (2011) 1.07
Three repeat isoforms of tau inhibit assembly of four repeat tau filaments. PLoS One (2010) 1.06
Milestones in PD genetics. Mov Disord (2011) 1.04
First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann Neurol (2010) 1.03
LRRK2 and human disease: a complicated question or a question of complexes? Sci Signal (2012) 1.02
Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background. Neurobiol Aging (2005) 1.02
Synuclein accumulation is associated with cell-specific neuronal death after spinal cord injury. J Comp Neurol (2012) 0.99
Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism. Ann Neurol (1999) 0.94
Hypokinesia and reduced dopamine levels in zebrafish lacking β- and γ1-synucleins. J Biol Chem (2011) 0.94
Alanine-to-threonine substitutions and amyloid diseases: butyrylcholinesterase as a case study. Chem Biol Interact (2010) 0.87
Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity. PLoS One (2010) 0.87
Alpha-synuclein deficiency affects brain Foxp1 expression and ultrasonic vocalization. Neuroscience (2010) 0.86
alpha-Synuclein A53T substitution associated with Parkinson disease also marks the divergence of Old World and New World primates. Genomics (2004) 0.86
Suppression of α-synuclein toxicity and vesicle trafficking defects by phosphorylation at S129 in yeast depends on genetic context. Hum Mol Genet (2012) 0.85
Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease. Brain (2003) 0.83
Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe. Hum Mutat (2012) 0.83